Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma

David A. Solomon, Jung Sik Kim, Julia C. Cronin, Zita Sibenaller, Timothy Ryken, Steven A. Rosenberg, Habtom Ressom, Walter Jean, Darell Bigner, Hai Yan, Yardena Samuels, Todd Waldman

Research output: Contribution to journalArticlepeer-review

97 Scopus citations

Abstract

An additional tumor suppressor gene on chromosome 9p telomeric to the CDKN2A/B locus has long been postulated to exist. Using Affymetrix 250K single nucleotide polymorphism arrays to screen for copy number changes in glioblastoma multiforme (GBM), we detected a high frequency of deletions of the PTPRD gene, which encodes a receptor protein tyrosine phosphatase at chromosome 9p23-24.1. Missense and nonsense mutations of PTPRD were identified in a subset of the samples lacking deletions, including an inherited mutation with somatic loss of the wild-type allele. We then sequenced the gene in melanoma and identified 10 somatic mutations in 7 of 57 tumors (12%). Reconstitution of PTPRD expression in GBM and melanoma cells harboring deletions or mutations led to growth suppression and apoptosis that was alleviated by both the somatic and constitutional mutations. These data implicate PTPRD in the pathogenesis of tumors of neuroectodermal origin and, when taken together with other recent reports of PTPRD mutations in adenocarcinoma of the colon and lung, suggest that PTPRD may be one of a select group of tumor suppressor genes that are inactivated in a wide range of common human tumor types.

Original languageEnglish (US)
Pages (from-to)10300-10306
Number of pages7
JournalCancer Research
Volume68
Issue number24
DOIs
StatePublished - Dec 15 2008
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma'. Together they form a unique fingerprint.

Cite this